The willingness to pay for health improvement under comorbidity ambiguity

Yoichiro Fujii; Yusuke Osaki

doi:10.1016/j.jhealeco.2019.04.002

The willingness to pay for health improvement under comorbidity ambiguity

Yoichiro Fujii, Yusuke Osaki^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.

Original language	English
Pages (from-to)	91-100
Number of pages	10
Journal	Journal of Health Economics
Volume	66
DOIs	https://doi.org/10.1016/j.jhealeco.2019.04.002
Publication status	Published - 2019 Jul
Externally published	Yes

Keywords

Comorbidity ambiguity
Cost-benefit analysis
Smooth ambiguity model
α-maxmin model

ASJC Scopus subject areas

Health Policy
Public Health, Environmental and Occupational Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jhealeco.2019.04.002

Cite this

@article{5dc170b10c13467a882c752eeec807cf,

title = "The willingness to pay for health improvement under comorbidity ambiguity",

abstract = "Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.",

keywords = "Comorbidity ambiguity, Cost-benefit analysis, Smooth ambiguity model, α-maxmin model",

author = "Yoichiro Fujii and Yusuke Osaki",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",

year = "2019",

month = jul,

doi = "10.1016/j.jhealeco.2019.04.002",

language = "English",

volume = "66",

pages = "91--100",

journal = "Journal of Health Economics",

issn = "0167-6296",

publisher = "Elsevier",

}

TY - JOUR

T1 - The willingness to pay for health improvement under comorbidity ambiguity

AU - Fujii, Yoichiro

AU - Osaki, Yusuke

PY - 2019/7

Y1 - 2019/7

N2 - Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.

AB - Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.

KW - Comorbidity ambiguity

KW - Cost-benefit analysis

KW - Smooth ambiguity model

KW - α-maxmin model

UR - http://www.scopus.com/inward/record.url?scp=85066108997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066108997&partnerID=8YFLogxK

U2 - 10.1016/j.jhealeco.2019.04.002

DO - 10.1016/j.jhealeco.2019.04.002

M3 - Article

C2 - 31136854

AN - SCOPUS:85066108997

SN - 0167-6296

VL - 66

SP - 91

EP - 100

JO - Journal of Health Economics

JF - Journal of Health Economics

ER -

The willingness to pay for health improvement under comorbidity ambiguity

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this